markdownabstract__Abstract__ The Erasmus MC University Medical Center has a longstanding tradition in fundamental and clinical research in the field of lysosomal storage diseases with a special focus on Pompe disease. The pioneering work of our research group has resulted in the successful implementation of enzyme replacement therapy (ERT) for patients with Pompe disease, turning it into the first treatable hereditary neuromuscular disorder. In 2007, the Center for Lysosomal and Metabolic diseases at Erasmus MC (formerly known as ‘Pompe Center’) was appointed by the Dutch health authority as the Center of Excellence for this particular disease. In this function, the center coordinates the care of all patients combined with basic ...
__Abstract__ The introduction of enzyme-replacement therapy (ERT) in 2006 has dramatically increa...
__Abstract__ Pompe disease, also known as glycogen storage disorder type II and acid maltase defi...
Pompe disease, glycogen storage disease type II (GSD II), glycogenosis type II, and acid maltase def...
textabstractPompe disease is a lysosomal storage disorder caused by deficiency of the enzyme acid a...
Pompe disease is a metabolic myopathy. Since the first description of the disease in 1932 by J.C. P...
textabstractAbstract. Background: Enzyme replacement therapy (ERT) in adults with Pompe disease, a p...
Background: Enzyme replacement therapy (ERT) in adults with Pompe disease, a progressive neuromuscul...
ABSTRACT Pompe disease (PD) is a potentially lethal illness involving irreversible muscle damage res...
Pompe disease is a genetic disorder produced by mutations in the GAA gene leading to absence or redu...
BACKGROUND AND PURPOSE: Pompe disease is a rare inheritable muscle disorder for which enzyme replace...
Pompe disease (PD) is a metabolic myopathy caused by the deficiency of the lysosomal hydrolase acid ...
Ilka Schneider, Stephan Zierz Department of Neurology, Martin Luther University Halle-Wittenberg, Ha...
Pompe disease is a rare lysosomal storage disorder characterized by muscle weakness and wasting. The...
Pompe disease is an autosomal recessive metabolic myopathy caused by the deficiency of the lysosomal...
textabstractBackground: Pompe disease is a rare lysosomal storage disorder characterized by muscle w...
__Abstract__ The introduction of enzyme-replacement therapy (ERT) in 2006 has dramatically increa...
__Abstract__ Pompe disease, also known as glycogen storage disorder type II and acid maltase defi...
Pompe disease, glycogen storage disease type II (GSD II), glycogenosis type II, and acid maltase def...
textabstractPompe disease is a lysosomal storage disorder caused by deficiency of the enzyme acid a...
Pompe disease is a metabolic myopathy. Since the first description of the disease in 1932 by J.C. P...
textabstractAbstract. Background: Enzyme replacement therapy (ERT) in adults with Pompe disease, a p...
Background: Enzyme replacement therapy (ERT) in adults with Pompe disease, a progressive neuromuscul...
ABSTRACT Pompe disease (PD) is a potentially lethal illness involving irreversible muscle damage res...
Pompe disease is a genetic disorder produced by mutations in the GAA gene leading to absence or redu...
BACKGROUND AND PURPOSE: Pompe disease is a rare inheritable muscle disorder for which enzyme replace...
Pompe disease (PD) is a metabolic myopathy caused by the deficiency of the lysosomal hydrolase acid ...
Ilka Schneider, Stephan Zierz Department of Neurology, Martin Luther University Halle-Wittenberg, Ha...
Pompe disease is a rare lysosomal storage disorder characterized by muscle weakness and wasting. The...
Pompe disease is an autosomal recessive metabolic myopathy caused by the deficiency of the lysosomal...
textabstractBackground: Pompe disease is a rare lysosomal storage disorder characterized by muscle w...
__Abstract__ The introduction of enzyme-replacement therapy (ERT) in 2006 has dramatically increa...
__Abstract__ Pompe disease, also known as glycogen storage disorder type II and acid maltase defi...
Pompe disease, glycogen storage disease type II (GSD II), glycogenosis type II, and acid maltase def...